A new real-world outcomes thread emphasized the need to verify whether therapies reach their intended targets. In imaging-led work, researchers described approaches intended to show whether immunotherapy drugs actually arrive at tumor sites—an ongoing challenge as clinicians try to predict response earlier and reduce unnecessary exposure. Such tools align with broader efforts to link biomarkers to actionable decisions.